NFE2L2 and cancer: Following effective silencing of NFE2L2 with siRNA to evaluate the impact on ESR1 expression (Figure 5), an elevated expression of ESR1 in the NFE2L2 downregulated cancer cell lines OVCAR3 (p = 0.003) and ES2 was noted (p < 0.001).